The Sydney Biomedical Accelerator (SBA), a partnership between the University of Sydney, the NSW Government and Sydney Local Health District, has been awarded the Partnership of the Year Award at Sydney Local Health District's 2022 Innovation and Excellence Awards.
First announced earlier this year, the SBA will create a first-in-Australia, 36,000m2 health, education, and research precinct co-located at Royal Prince Alfred Hospital and the University’s Camperdown campuses, within the Tech Central precinct.
The Accelerator will tackle some of our most complex health challenges, including cancer and neurodegenerative diseases and position Sydney as a global leader in biomedical research.
“The Sydney Biomedical Accelerator, a partnership between the University of Sydney, the NSW Government and Sydney Local Health District, will fast-track scientific discovery into health outcomes through connecting researchers, clinicians and industry together in one state-of-the-art biomedical research complex.
“We are thrilled the Sydney Biomedical Accelerator has been recognised as Partnership of the Year at the 2022 Innovation and Excellence Awards.
“This award is a testament to the value that the University of Sydney provides as a partner, and our ability to successfully build new partnerships that will realise shared goals and translate our research outputs into measurable benefits for society.”
The Partnership of the Year Award recognises teams who have collaborated through strategic partnerships to develop exceptional initiatives that will radically alter the future of patient, family, and community care in the Sydney Local Health District.
Early works for the Sydney Biomedical Accelerator commenced this year, with the complex to be established within the Tech Central precinct from 2026.
Vice-Chancellor and President, Professor Mark Scott AO, congratulated our colleagues and partners and spoke of the importance of the Sydney Biomedical Accelerator as a centrepiece of Sydney 2032.
“We are proud to partner with the NSW Government and Sydney Local Health District to create the Sydney Biomedical Accelerator, which will tackle some of our most complex health challenges including cancer and neurodegenerative diseases, and position Sydney as a global leader in biomedical research,” said Professor Scott.
“I would like to thank academic and professional colleagues for their outstanding work in building this partnership.
“Sydney 2032 establishes our aspiration for the University to be valued as consistently outstanding partners who are sought out in our local, national and international communities.
“This award is a well-deserved recognition of our value as a partner and the impact such partnerships can have.”